SIRIO Pharma (China), the global nutraceutical contract development and manufacturing organization (CDMO), has announced plans to commence work on a new production site in Chonburi, Thailand.
On the back of record revenues during 2023 – Sirio announced in May, 2024 a 42.87 percent year-on-year revenue rise to $508 million [€469 million] – the CDMO is continuing its global expansion by building its first manufacturing plant in Asia outside of China. The integrated site in Thailand will become Sirio’s eighth worldwide, complementing existing facilities in the E.U., two in the U.S., and four large-scale production sites in China. This strategic move aims to bolster the company’s presence and capabilities in the fast-growing APAC region.
Sirio’s board has approved a potential total investment of up to $40 million for the project. The new site will include state-of-the-art gummy production facilities, with additional automatic packaging lines for nutraceutical dose forms.
“We have invested in a new multipurpose nutraceutical plant in Thailand to meet the needs of our customers in Southeast Asia. In recent years, this has been one of the fastest-growing regions, and we can better serve our customers here with local resources,” said Alex Du, general manager, Asia Pacific BU at Sirio Pharma. “Our global strategy is to support international customers with local production resources in key markets. With our eighth site, this provides even greater flexibility in resources and options for local manufacturing across different regions.”
Ahead of the new plant’s construction, Sirio will also open a new office in Singapore’s central business district later this month, as part of wider efforts to further increase regional customer and trade association partnering.
The Chonburi project is pending review and approval from relevant Chinese and Thai regulators, with construction start date and more details to follow in 2025.
For more information, visit www.siriopharma.com.
